Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.

Jeffrey S HeierAllen C HoDavid S BoyerKarl CsakyRobert VittiLorah PerleeKaren W ChuFriedrich AsmusSergio LealOliver ZeitzYenchieh ChengThomas SchmelterDavid M Brown

Published in: Journal of vitreoretinal diseases (2022)

In nAMD, nesvacumab + aflibercept showed no additional BCVA or CST benefit over IAI monotherapy.

Keyphrases

age related macular degeneration
combination therapy
open label
study protocol
optical coherence tomography
double blind
endothelial cells